ライフサイエンスコーパス: ADEM

1 ADEM/MDEM patients were more likely to have blood leucoc

2 The mean follow-up for the 35 ADEM/MDEM patients was 5.78 years (range 1.0-15.4 years)

3 ed a risk difference (excess risk) of TM and ADEM for each vaccine.

4 We identified all cases of TM and ADEM in the Vaccine Safety Datalink population.

5 Defining ADEM and distinguishing it from multiple sclerosis early

6 ), and acute disseminated encephalomyelitis (ADEM) (8%).

7 s with acute disseminated encephalomyelitis (ADEM) associated with Group A beta hemolytic streptococc

8 S) and acute disseminated encephalomyelitis (ADEM) have been difficult to study and treat due to the

9 Acute disseminated encephalomyelitis (ADEM) is a demyelinating disorder most common in childho

10 th non-acute disseminated encephalomyelitis (ADEM) presentations, as did the 2005 McDonald criteria.

11 r than acute disseminated encephalomyelitis (ADEM) recruited from 40 secondary and tertiary centres i

12 s with acute disseminated encephalomyelitis (ADEM) selectively bound the folded MOG tetramer, whereas

13 while acute disseminated encephalomyelitis (ADEM), brain, or brainstem onset was predominant among 6

14 TM) or acute disseminated encephalomyelitis (ADEM), but the evidence for a causal association is inco

15 luding acute disseminated encephalomyelitis (ADEM), one episode of transverse myelitis or optic neuri

16 8 with acute disseminated encephalomyelitis (ADEM), seven with multiphasic disseminated encephalomyel

17 o with acute disseminated encephalomyelitis (ADEM), two with ON, one with transverse myelitis (TM) an

18 n with acute disseminated encephalomyelitis (ADEM).

19 s like acute disseminated encephalomyelitis (ADEM).

20 2), or acute disseminated encephalomyelitis (ADEM; 8/25 [32%] vs 9/468 [2%]; p < 0.001), and less com

21 with acute disseminating encephalomyelitis (ADEM), but the clinical and neuroradiological characteri

22 For ADEM, it is speculated that a preceding infection is the

23 For ADEM, there was no statistically significant increased r

24 at MOG is a more prominent target antigen in ADEM than MS.

25 By contrast, in ADEM/MDEM there was absolute and relative periventricula

26 ollowing findings were more commonly seen in ADEM/MDEM presentation compared with the multiple sclero

27 ing syndromes in these 116 patients included ADEM (46 [68%]), encephalitis other than ADEM (22 [19%])

28 Phenotypes of poor prognosis included ADEM-like relapses progressing to leukodystrophy-like fe

29 in those with suspected MS included initial ADEM phenotype, younger age at disease onset, and lack o

30 an advection-diffusion equation with memory (ADEM) whose parameters are obtained from a mean group ve

31 In younger children with a non-ADEM presentation, PPV of the 2010 criteria was only 55%

32 red to 18% of patients with nonstreptococcal ADEM.

33 There was a possible association of ADEM with Tdap vaccine, but the excess risk is not likel

34 is not likely to be more than 1.16 cases of ADEM per million vaccines administered.

35 ine doses, only 7 cases of TM and 8 cases of ADEM were vaccinated during the primary exposure window

36 te aimed at differential characterization of ADEM and childhood multiple sclerosis have been retrospe

37 not suited for application in the context of ADEM-like presentations.

38 ill be required to arrive at a definition of ADEM so as to distinguish it from childhood multiple scl

39 These differences in the presentation of ADEM/MDEM compared with multiple sclerosis may help in t

40 utoantibodies were identified in a subset of ADEM but only rarely in adult-onset MS cases, indicating

41 bination with other presentations [ie, ON or ADEM, brain, or brain stem]) was associated with decreas

42 nization and subsequent development of TM or ADEM.

43 ies, outcome and MOG status of 33 paediatric ADEM prospectively studied were reviewed.

44 nificantly elevated in the poststreptococcal ADEM group compared with neurological controls.

45 ia in 80% of patients with poststreptococcal ADEM, compared to 18% of patients with nonstreptococcal

46 ABGA in the patients with poststreptococcal ADEM.

47 ded ADEM (46 [68%]), encephalitis other than ADEM (22 [19%]), optic neuritis (20 [17%]), myelitis (13

48 hort A) and 296 with encephalitis other than ADEM (cohort B) were recruited.

49 The outcome in the ADEM patients was mixed; 57% of patients made a complete

50 Seizures occurred only in the ADEM/MDEM group (17 versus 0%, not significant).

51 resolution in 90% and no new lesions in the ADEM/MDEM group.

52 The presentation findings of the ADEM/MDEM group were compared with those of the multiple

53 s ratio for Tdap exposure 5-28 days prior to ADEM onset was 15.8 (95% confidence interval [CI], 1.2-4

54 Some children with ADEM develop additional temporally remote episodes of de

55 None of the 50 children with ADEM met clinical criteria for MS, but 10 met 2010 and 4

56 entified MOG-Abs in adults and children with ADEM, seizures, encephalitis, anti-aquaporin-4-antibody

57 -1:20 480) were detected in 19 children with ADEM.

58 atients [68.1%]), including 41 patients with ADEM (59.4%).

59 Patients with ADEM with MOG antibodies in our cohort had a uniform MRI

60 AR)-Ab was found in two; one presenting with ADEM and one with ON.

61 were positive in three; one presenting with ADEM, one with ON and one with CIS.